Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Update

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,710,000 shares, a decline of 5.5% from the May 31st total of 1,810,000 shares. Based on an average trading volume of 302,500 shares, the short-interest ratio is presently 5.7 days.

Actinium Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ATNM opened at $6.96 on Wednesday. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $10.24. The stock has a market cap of $207.27 million, a price-to-earnings ratio of -4.07 and a beta of 0.20.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, April 26th. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Equities analysts expect that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, May 5th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, June 17th. Stephens began coverage on Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, Maxim Group increased their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.60.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Creative Financial Designs Inc. ADV lifted its holdings in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 3,175 shares during the last quarter. Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the 1st quarter valued at approximately $78,000. Virtu Financial LLC raised its stake in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 62,459 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after acquiring an additional 82,113 shares in the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.